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 Menstrual bleeding patterns in adolescents using etonogestrel 
(ENG) implant 
 Amit M.  Deokar , Wendy  Jackson and Hatim A.  Omar *  
 Department of Pediatrics ,  Division of Adolescent 
Medicine and Department of Obstetrics and Gynecology, 
Kentucky Women ’ s Health, University of Kentucky, 
Lexington, KY ,  USA 
 Abstract 
 Background: Etonogestrel (ENG) implant is an effective 
method of contraception. The implant is designed to provide 
contraceptive effi cacy for 3  years with a relatively quick return 
of fertility upon its removal. Menstrual irregularities are not 
uncommon on long-acting progestins and can often be the 
factor for discontinuation or removal. A retrospective chart 
analysis was done on 58 patients who chose to be on the ENG 
implant. Age ranged from 12 to 24  years. The cycle ranged 
from 1 to 17  months. The mean length of use of the implant 
was 10.9  months. Over the 20-month period, 13 ENG implants 
were removed because of menstrual bleeding problems. 
 Method: We conducted a chart review of the adolescent 
patients who received the ENG implant in our adolescent 
clinic. An analysis was done based on symptoms experienced 
by patients who were on the ENG implant and their manage-
ment, which in some cases resulted in its removal. 
 Setting : The data is presented on adolescent and young adult 
patients who receive their reproductive care in the Adolescent 
Medicine Clinic at the University of Kentucky, Lexington, 
KY, USA. 
 Conclusions : ENG implant when used correctly and as indi-
cated is extremely effective in providing contraception for 
up to 3  years. However, menstrual irregularities can be very 
troublesome and often a reason for its removal. In our experi-
ence, 22.4 % (13 out of the 58 subjects) had menstrual prob-
lems post-insertion that led to its removal. It is crucial for a 
clinician to inform and be informed about such side effects. 
 Keywords:  adolescents;  contraceptives;  depot medroxypro-
gesterone acetate;  doxycycline;  ethinyl estradiol;  etonogestrel 
(ENG);  mifepristone;  progesterone/progestin. 
 Introduction 
 There are more than 20 million women worldwide who use 
long-acting progesterone-only contraceptives  (1, 2) . These 
are extremely effective contraceptives with a failure rate of 
0.3 % – 1.0 % annually  (2) . Etonogestrel (ENG) implant market-
ed as Implanon ™ is a progestin-only subdermal contraceptive 
implant that was fi rst marketed in Indonesia in 1998  (3, 4) . 
Since then, more than 3 million implants have been dispensed 
throughout the world. It was fi rst approved in the US by the 
Food and Drug Administration (FDA) in 2006  (3, 5) . It consists 
of a sterile non-biodegradable single rod implant (dimension: 
4  cm × 2  mm) that contains 68  mg of the biologically active 
metabolite of Desogestrel called Etonogestrel (ENG)  (1, 3 – 5) . 
There is a gradual decline in the hormone released from ap-
proximately 60–70  µ g/day following a few weeks after its 
insertion to approximately 25 – 30  µ g by the end of 3  years  (4, 
6, 7) . Some important features of the implant are as follows: 
(i) mechanism of action of the ENG implant; (ii) one of the 
most common reasons for its discontinuation, i.e., menstrual 
irregularities; and (iii) data from the chart review of patients in 
our clinic who experienced menstrual irregularities. 
 The contraceptive mechanisms of the ENG implant are as 
follows  (4, 6, 7) : (a) suppression of luteinizing hormone surge 
(although the follicle stimulating hormone is also suppressed, 
but only partially); (b) increased viscosity of the cervical 
mucus that impedes sperm penetration; and (c) alteration 
(thinning) of the endometrium. 
 At present, clinicians are required to undergo training con-
ducted by Organon (manufacturer) before they can insert the 
Implanon ™ in a patient. Within 1 – 2  weeks of removal of the 
Implanon ™ , fertility is reversed  (6, 8) . There are some other 
key clinical features of Implanon ™ that a clinician needs to be 
aware of and are listed below  (4, 7, 9) . 
 For a patient who seeks a long-acting progesterone 1. 
implant, the clinician must provide adequate pre- and 
post-insertion counseling. This is very crucial because 
menstrual abnormalities continue to be the most common 
reason for discontinuation and removal of the implant. 
Even though data might be inconclusive on progesterone 
directly increasing the risk of thrombosis, women should 
still be counseled to refrain from tobacco smoke. 
 Informed consent must be obtained before the insertion, 2. 
removal or replacement. It is of utmost importance for the 
patient to know that Implanon ™ does not prevent sexually 
transmitted infections, and appropriate measures must be 
taken to prevent such infections. 
 During its clinical trials, Implanon 3. ™ was not studied in 
women who weighed more than 130 % of their ideal body 
weight. The serum concentration of ENG is inversely 
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proportional to the body weight and the length of time for 
which the implant was in place. 
 Over the course of multiple years, the ENG implant is 4. 
more cost-effective than combined oral contraceptives. 
 Unintended pregnancies in the fi rst year of the Implanon 5. ™ 
use are estimated to be <0.05 % (1 in 100 users). 
 As a result of drug interactions, plasma levels of ENG can 6. 
vary especially if the patient is on medications that induce 
or inhibit the hepatic enzymes. 
 When compared to depot medroxyprogesterone acetate, 7. 
the effect of Implanon ™ on bone mineral density (BMD) is 
reassuring. In contrast, pregnancy and lactation have rela-
tively worse effects on bone density. BMD usually returns 
to baseline within a few years of stopping the long-acting 
progesterone containing contraceptives. 
 Side effects 
 Contraceptives containing long-acting progesterone are invalu-
able in preventing teen pregnancy. Implanon ™ is a good 
example of one such contraceptive. All hormonal contracep-
tives have a certain side-effect profi le, including the ENG 
implant. This article focuses on menstrual irregularities and 
problems associated with its use and how they can infl uence 
patients desire to opt for its discontinuation/removal. 
 There are varying patterns of menstrual abnormalities that 
are possible with Implanon ™ use. These include amenorrhea, 
prolonged and heavy bleeding, irregular bleeding, spotting, 
and an unpredictable bleeding pattern, etc.  (1, 3, 4, 7) . The 
most frequent reason reported by women is unpredictable 
and irregular vaginal bleeding. In Implanon ™ users, the 
bleeding pattern is most likely to vary in the fi rst 3  months 
after insertion  (6) . This can lead to frustration and poor qual-
ity of life. These issues can cause anxiety and discontent in 
the teenager ’ s mind. It is advisable to keep a menstrual diary 
that will help the clinician to manage the menstrual problems 
effectively. 
 There are several reasons cited that play a role in the bleed-
ing irregularities in progesterone users. These include altered 
endometrial matrix metalloproteinase (MMP), vascular fragil-
ity, irregular endometrial blood vessels, decreased glandular 
and stromal support, and decreased integrity of the epithe-
lium  (1, 10) . According to Weisberg et al.  (1) and Monsour 
et al.  (11) , a review of 11 clinical trials involving Implanon ™ 
(n = 923) revealed that 11.3 % of the users discontinued it 
because of prolonged and frequent menstrual bleeding  (1, 11) . 
Differences in culture, personal and social factors, and toler-
ance to bleeding irregularities can largely affect one ’ s deci-
sion to discontinue with Implanon ™  (6) . 
 Chart review 
 From February 2008 to October 2009, a total number of 58 
patients received Implanon ™ , which was placed by certifi ed 
and trained clinicians in the Division of Adolescent Medi-
cine, University of Kentucky, Lexington, KY, USA. The 
age range of the patients was between 12 and 24  years. The 
maximum number days the patients retained their Implanon ™ 
post-insertion varied from 26  days to 17  months before they 
were electively discontinued and removed. Out of the 58 
patients, 13 (22.4 % ) requested removal and discontinuation 
of Implanon ™ primarily because of menstrual irregularities. 
 The menstrual problems ranged from spotting to an overt 
period. The duration of bleeding post-ENG implant was cat-
egorized into 1 – 7  days and continuous (more than 7  days and 
multiple breakthrough bleeding episodes). The management 
of such bleeding patterns included use of combination con-
traceptive pills to removal of the implant. Based on our data, 
this is one of the highest percentages of patients opting for its 
discontinuation and removal. 
 Management of menstrual irregularities 
 A variety of treatment options are available for menstrual 
irregularities associated with Implanon ™ use. Some are more 
effective than others and thus need to be patient-specifi c  (1, 
7) . It is crucial to not use any of these recommendations in 
undiagnosed vaginal bleeding.
 Doxycycline 100  mg twice daily for 5  days. The inhibition • 
of MMP mediated degeneration of the endometrial matrix 
is believed to be the mechanism of its action. 
 Mifepristone (25  mg) twice for 1  day followed by ethinyl • 
estradiol (EE) 10  µ g twice a day for 4  days. Such a regi-
men depends on the availability of mifepristone and that 
there are no contraindications for its use along with EE. 
Mifepristone works by stabilizing the endometrium by its 
rapid repair action. 
 Combination oral contraceptives. The dose and duration • 
is a matter of the clinician ’ s preference and patient ’ s 
tolerability. 
 Non-streroidal anti-infl ammatory drugs (NSAIDs). An ex-• 
ample is high dose of ibuprofen (800  mg three times a day) 
or mefenamic acid (500  mg three times a day) for 5  days. 
NSAIDs act by blocking the prostaglandin synthesis. 
Platelet aggregation and endometrial vasoconstriction can 
also play a crucial role. 
 Conclusion 
 Long-acting progesterone contraceptives are extremely 
effective in preventing teen pregnancies. Some contracep-
tives such as Implanon ™ also allow relatively quick return 
of fertility. They can be very cost-effective when used over 
multiple years. However, menstrual irregularities and prob-
lems are some of the major reasons for its discontinuation 
and removal. Therefore, it is very important for the clinician 
to provide the patient with adequate pre-, post-insertion, and 
pre-removal counseling so that an educated decision can be 
facilitated. 
 There are patient specifi c recommendations to manage 
the bleeding irregularities and include a choice of doxycy-
cline, EE, mifepristone, combination oral contraceptives, 
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and NSAIDs. Patients who discontinue Implanon ™ should be 
given an alternate contraceptive recommendation to prevent 
an unintended pregnancy. 
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